Home › All Companies › BBNX

Beta Bionics, Inc. (BBNX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-21

Key Insights

  • Beta Bionics filed a routine Q1 2026 earnings announcement on April 21, 2026, disclosing financial results for the period ended March 31, 2026 through a press release attachment.
  • The company is classified as an emerging growth company, which provides certain regulatory relief and reduced disclosure obligations under securities laws.
  • The filing contains minimal substantive information within the 8-K itself, with all financial details relegated to the non-filed press release exhibit, limiting investor access to officially filed disclosures.
Sentiment: Neutral Significance: 2/10
View Original Filing →
Quarterly Report Filed: 2026-04-21

Key Insights

  • The filing contains extensive tagging metadata related to customer concentration risks across multiple distributor channels (A-H) and product categories (single-use vs durable medical equipment), suggesting Beta Bionics has notable customer concentration exposure that warrants investor scrutiny.
  • Multiple references to restricted stock units (RSUs) and employee stock options with various vesting dates throughout 2025-2026 indicate active equity compensation programs, which could represent meaningful dilution to existing shareholders.
  • The presence of net operating loss carryforwards and R&D tax credit carryforwards in the filing suggests the company has generated significant tax losses, potentially providing future tax benefits but also indicating cumulative unprofitability through recent periods.
  • References to accumulated other comprehensive income changes across multiple periods suggest the company holds investment securities with marked-to-market adjustments, indicating exposure to interest rate and market volatility risks.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Annual Report Filed: 2026-02-24

Key Insights

  • Beta Bionics is a medical device company developing an artificial pancreas system, a key focus area in the diabetes market. The company has made progress with regulatory approval and is preparing for a planned IPO in January 2025.
  • The company has experienced revenue growth from its durable medical equipment and pharmacy benefit plan channels, though it remains pre-revenue overall. Continued investments in R&D and manufacturing capabilities are expected to drive future growth.
  • Beta Bionics has a substantial net operating loss and R&D tax credit carryforward, which could provide future tax benefits as the company becomes profitable. However, the fair value of certain warrant liabilities and equity instruments introduce accounting complexity.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-02-17

Key Insights

  • Beta Bionics, Inc. (BBNX) announced its Q4 and full-year 2025 financial results, potentially providing investors with insight into the company's recent performance.
  • The filing does not mention any material agreements, leadership changes, or other significant corporate events, suggesting a routine quarterly earnings report.
  • As an emerging growth company, Beta Bionics may have elected to take advantage of extended transition periods for complying with new or revised financial accounting standards, which could impact the company's financial reporting.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Current Report Filed: 2026-01-30

Key Insights

  • The company received a warning letter from the FDA citing deficiencies in its Quality Management System, Medical Device Reporting, and Correction and Removals, which may lead to further regulatory action if not resolved.
  • The company is preparing a written response to the FDA and has already implemented some corrective actions, but there is uncertainty around the timeline for resolution and the FDA's satisfaction with the company's response.
  • Despite the regulatory issues, the company still expects to launch the commercialization of its Mint product by the end of 2027, indicating the potential impact may be limited.
Sentiment: Negative Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • The Form 4 filing indicates that Gerard J. Michel, a director of Beta Bionics, Inc., has acquired 3,997 shares of the company's common stock through a restricted stock unit award.
  • The transaction suggests that the director has increased his direct ownership in the company, potentially signaling his confidence in the company's future prospects.
  • Investors should monitor insider trading activities, as they can provide insights into management's views on the company's valuation and growth potential.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Danny L. Dearen, a director of Beta Bionics, Inc., acquired 3,997 shares of the company's common stock through a restricted stock unit award under the 2025 Equity Incentive Plan.
  • This insider transaction suggests Dearen's confidence in the company's future and aligns his interests with those of other shareholders.
  • The acquisition of these shares increases Dearen's direct beneficial ownership in Beta Bionics to 15,244 shares.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Adam Lezack, a director of Beta Bionics, Inc., has acquired 3,997 shares of the company's common stock. This insider buying activity may signal the director's confidence in the company's prospects.
  • The transaction was an acquisition of restricted stock units, which suggests the director is being compensated and incentivized to align his interests with those of the company and its shareholders.
  • The number of shares acquired represents a relatively small portion of the director's total beneficial ownership, which stands at 12,432 shares following the reported transaction.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Christy Jones, a director of Beta Bionics, Inc., acquired 3,997 shares of common stock through a restricted stock unit award, increasing her direct beneficial ownership to 15,244 shares.
  • The acquisition of shares by a director suggests their confidence in the company's future performance and aligns their interests with those of other shareholders.
  • Investors should monitor insider trading activity, as it can provide insights into management's perspectives on the company's prospects.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Insider Maria Palasis acquired 3,997 shares of Beta Bionics, Inc. (BBNX), increasing her direct ownership to 12,432 shares.
  • The transaction was through a restricted stock unit award granted under the company's 2025 Equity Incentive Plan, suggesting the company is incentivizing and retaining key leadership.
  • Insider buying can signal management's confidence in the company's prospects, which may be positive for investors.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-14

Key Insights

  • Sean Carney, a director of Beta Bionics, Inc., has acquired 3,997 shares of the company's common stock, increasing his direct ownership to 15,244 shares.
  • The acquisition appears to be a restricted stock unit award granted under the company's 2025 Equity Incentive Plan, suggesting an alignment of Carney's interests with those of the company and its shareholders.
  • Insider transactions, such as this acquisition, can provide insight into management's confidence in the company's prospects and their commitment to creating shareholder value.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-01-08

Key Insights

  • Beta Bionics, Inc. has issued preliminary, unaudited fourth quarter 2025 topline financial results, indicating the company's performance and progress during the quarter.
  • The company's common stock is traded on the Nasdaq Global Market under the ticker symbol BBNX, providing investors with a publicly traded investment opportunity.
  • Beta Bionics, Inc. has identified itself as an emerging growth company, which may allow it to take advantage of certain regulatory exemptions and reporting requirements.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-07

Key Insights

  • Mike Mensinger, the Chief Product Officer of Beta Bionics, Inc., has sold 2,200 shares of the company's common stock pursuant to a pre-planned 10b5-1 trading plan.
  • The shares were sold at a weighted average price of $30.1005 per share, and Mensinger still holds 80,752 shares directly after the transaction.
  • This insider sale, while routine, could indicate Mensinger's confidence in the current stock price or a need for personal liquidity, and should be monitored by investors for any larger or more frequent selling patterns.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.